The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Semiglazova T.Iu.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Semiglazov V.V.

N.N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia

Filatova L.V.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Krivorot'ko P.V.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Latipova D.Kh.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Gershanovich M.L.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Metastatic breast cancer: Innovation targeted agents

Authors:

Semiglazova T.Iu., Semiglazov V.V., Filatova L.V., Krivorot'ko P.V., Paltuev R.M., Latipova D.Kh., Gershanovich M.L.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(2): 94‑99

Read: 3768 times

Download PDF (RU)
Contact the author
Table of contents

METASTATIC BREAST CANCER: INNOVATION TARGETED AGENTS
METASTATIC BREAST CANCER: INNOVATION TARGETED AGENTS

To cite this article:

Semiglazova TIu, Semiglazov VV, Filatova LV, Krivorot'ko PV, Paltuev RM, Latipova DKh, Gershanovich ML. Metastatic breast cancer: Innovation targeted agents. P.A. Herzen Journal of Oncology. 2012;1(2):94‑99. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Rese­ction of sternum body with ante­rior segments of ribs II—III and bone replacement with indi­vidual tita­nium implant. Piro­gov Russian Journal of Surgery. 2025;(1):68-73
Abstract:

The paper considers the possibilities of overcoming resistance to drug treatment for metastatic breast cancer (MBC) by using the innovation targeted agents: pertuzumab and T-DM1 in patients with HER-2-positive MBC, including in those with its progression after trastuzumab-containing regimens and an anti-mTOR inhibitor (everolimus) in patients with hormone-dependent (estrogen receptor-positive) BC without HER2 amplification, who are resistant to nonsteroidal aromatase inhibitors.

Keywords:

metastatic breast cancer
trastuzumab
pertuzumab
T-DM1
everolimus

Authors:

Semiglazova T.Iu.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Semiglazov V.V.

N.N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia

Filatova L.V.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Krivorot'ko P.V.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Paltuev R.M.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Latipova D.Kh.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Gershanovich M.L.

FGBU "NII onkologii im. N.N. Petrova" Minzdravsotsrazvitiia Rossii, Sankt-Peterburg

Close metadata

References:

  1. Belousov Yu.B. Innovatsionnye lekarstvennye preparaty v real'noi klinicheskoi praktike. Mediko-sotsial'nye aspekty otechestvennogo zdravookhraneniya i sovremennoi farmakologii: Izbr. lektsii. M.; 2005. 7-19.
  2. Perevodchikova N.I., Stenina S.M., red. Gormonoterapiya raka molochnoi zhelezy. M.; 2010. 71 s.
  3. Prikaz №965 ot 23 oktyabrya 2009 goda Ministerstva promyshlennosti i torgovli Rossiiskoi Federatsii "Ob utverzhdenii strategii razvitiya farmatsevticheskoi promyshlennosti Rossiiskoi Federatsii na period do 2020 goda".
  4. Semiglazov V.F. Strategicheskie i prakticheskie podkhody k resheniyu problemy raka molochnoi zhelezy. Voprosy onkologii. 2012; 58 (2): 148-52.
  5. Semiglazov V.F., Manikhas A.G., Semiglazova T.Yu., Bessonov A.A., Semiglazov V.V. Neoad''yuvantnaya sistemnaya terapiya raka molochnoi zhelezy. Rukovodstvo dlya vrachei. SPb.: Agraf+; 2012. 112 s.
  6. Semiglazova T.Yu. Novye perspektivy lecheniya bol'nykh HER2-pozitivnym rakom molochnoi zhelezy s metastazami v golovnoi mozg. Glava v monografii Semiglazova V.F., Semiglazova V.V., Manikhasa A.G. Rak molochnoi zhelezy. Khimioterapiya i targetnaya terapiya. M.: MEDpress-inform; 2012. 298-307.
  7. Bachelot T., Bourgier C., Cropet C. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 2012; 30: 2718-2724.
  8. Barok M., Isola J., Palyi-Krekk Z. et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 2007; 6: 2065-72.
  9. Barok M., Tanner M., Köninki K. et al. Trastuzumab-DM1 causes tumor growth inhibition by mitotic catastrophe in trastuzumab resistant breast cancer cells in vivo. Breast Cancer Res. 2011; 13. 46.
  10. Baselga J., Gelmon K.A., Verma S. et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010; 28: 1138-44.
  11. Baselga J., Campone M., Piccart M. et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 366 (6 suppl.): 520-9.
  12. Baselga J., Cortés J., Fumoleau P. et al. Pertuzumab and trastuzumab: re-response to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately - a new biological and clinical observation. San Antonio Breast Cancer Symposium 9-13 December 2009. Abstr. 5114.
  13. Baselga J., Cortes J., Kim S.-B. et al. for the CLEOPATRA Study Group. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N. Engl. J. Med. 2012; 366 (suppl. 2): 109-19.
  14. Baselga J., Semiglazov V., van Dam P. et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009; 27: 2630-7.
  15. Bianchi G., Kocsis J., Dirix L. et al. Patient-Reported Outcomes From a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine vs Trastuzumab Plus Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer, San-Antonio Breast Cancer Symposium December 6-10, 2011. Poster 1-12-02.
  16. Blackwell K.L., Miles D., Gianni L. et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J. Clin. Oncol. 2012; 30 (suppl.): abstr. LBA1.
  17. Boulay A., Rudloff J., Ye J. et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005; 11: 5319-28.
  18. Burris H.A. III, Rugo H.S., Vukelja S.J. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy. J. Clin. Oncol. 2011; 29 (suppl. 4): 398-405.
  19. Ellis P., Barrios C., Im Y., et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J. Clin. Oncol. 2011; 29 (suppl.): abstr. TPS102.
  20. Franklin M., Carey K., Vajdos F. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5: 317-28.
  21. Gianni L., Pienkowski T., Im Y-H, Semiglazov V. et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere'). Cancer Res. 2010; 70 (24 suppl.): abstr. S3-2.
  22. Girish S., Gupta M., Wang B. et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 2012; 69: 1229-40.
  23. Glantschnig H., Fisher J., Wesolowski G. et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003; 10: 1165-77.
  24. Gnant M., Baselga J., Rugo H. et al. Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J. Clin. Oncol. 2012; 30 (suppl.): abstr. 512.
  25. Hsieh A.C., Moasser M.M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer. 2007; 97: 453-7.
  26. Hurvitz S., Dirix L., Kocsis J. et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976). Eur. J. Cancer. 2011; 47 (suppl. 330): abstr. 5001.
  27. Junttila T., Li G., Parsons K. et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 2011; 128: 347-56.
  28. Kneissel M., Luong-Nguyen N.-H., Baptist M. et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004; 35: 1144-56.
  29. O'Shaughnessy J., Osborne C., Pippen J. et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol. 2011; 29 (suppl.): abstr. 1007.
  30. Phillips G., Li G., Dugger D. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Res. 2008; 68 (suppl. 22): 9280-90.
  31. Scheuer W., Friess F., Burtscher H. et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumour models. Cancer Res. 2009; 69: 9330-36.
  32. Vogel C. Highlights in Metastatic Breast Cancer From the 2011 San Antonio Breast Cancer Symposium (SABCS). Special Reporting on: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential With an Anthracycline-Containing or Concurrent With an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). Clinical Advances in Hematology & Oncology. 2012; 10 (suppl. 2): 9-10.
  33. Yamnik R., Holz K. mTOR/S6K and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alphaserine 167 phosphorylation. FEBS Lett. 2010; 584: 124-8.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.